These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 6169065

  • 1. Use of human chorionic gonadotropin and alpha-fetoprotein radioimmunoassays: specificity and apparent half-life determination after delivery and in patients with germ cell tumors.
    Mann K, Lamerz R, Hellmann T, Kümper HJ, Staehler G, Karl HJ.
    Oncodev Biol Med; 1980; 1(4-5):301-12. PubMed ID: 6169065
    [Abstract] [Full Text] [Related]

  • 2. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
    Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ.
    Cancer Res; 1990 Sep 15; 50(18):5904-10. PubMed ID: 1697503
    [Abstract] [Full Text] [Related]

  • 3. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W.
    Clin Cancer Res; 1996 Sep 15; 2(9):1565-70. PubMed ID: 9816334
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.
    Urology; 2010 Aug 15; 76(2):423-9.e2. PubMed ID: 20472276
    [Abstract] [Full Text] [Related]

  • 5. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD, Foster RS, Bihrle R, Donohue JP.
    Urology; 2007 Mar 15; 69(3):557-9. PubMed ID: 17382165
    [Abstract] [Full Text] [Related]

  • 6. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH, Sleijfer DT, Schraffordt Koops H, De Bruijn HW, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J.
    Oncodev Biol Med; 1981 Mar 15; 2(1-2):129-34. PubMed ID: 6170953
    [Abstract] [Full Text] [Related]

  • 7. Serum alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors.
    Lange PH.
    Natl Cancer Inst Monogr; 1978 Dec 15; (49):215-7. PubMed ID: 86163
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of alpha-fetoprotein, human chorionic gonadotropin and carcinoembryonic antigen in patients with primary intracranial germ cell tumors.
    Arita N, Ushio Y, Hayakawa T, Uozumi T, Watanabe M, Mori T, Mogami H.
    Oncodev Biol Med; 1980 Dec 15; 1(4-5):235-40. PubMed ID: 6169060
    [Abstract] [Full Text] [Related]

  • 9. Significance of radioimmunoassay of human chorionic gonadotropin and alpha fetoprotein in nonseminomatous germ cell tumors of the testis.
    Kausitz J, Hupka S, Cerný V, Bohunický L, Korec S.
    Neoplasma; 1980 Dec 15; 27(3):321-7. PubMed ID: 6161314
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemistry of germ cell tumors of the testis. Study of beta HCG and AFP.
    Caillaud JM, Bellet D, Carlu C, Droz JP.
    Prog Clin Biol Res; 1985 Dec 15; 203():139-40. PubMed ID: 2421327
    [No Abstract] [Full Text] [Related]

  • 11. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ.
    Cancer Res; 1982 Nov 15; 42(11):4855-61. PubMed ID: 6181870
    [Abstract] [Full Text] [Related]

  • 12. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T.
    Cancer; 2003 Oct 15; 98(8):1635-42. PubMed ID: 14534879
    [Abstract] [Full Text] [Related]

  • 13. Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy.
    Nisselbaum JS, Bosl GJ, Golbey RB, Schwartz DC, Schwartz MK.
    Ann Clin Lab Sci; 1984 Oct 15; 14(3):179-88. PubMed ID: 6203466
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of plasma tumor markers in germinal tumors of the testis].
    Blacker C, Feinstein MC, Roger M, Zimmer R, Scholler R.
    Ann Med Interne (Paris); 1984 Oct 15; 135(5):376-80. PubMed ID: 6207755
    [Abstract] [Full Text] [Related]

  • 15. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
    Christensen TB, Engbaek F, Marqversen J, Nielsen SI, Kamby C, von der Maase H.
    Br J Cancer; 1999 Jul 15; 80(10):1577-81. PubMed ID: 10408402
    [Abstract] [Full Text] [Related]

  • 16. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T.
    J Surg Oncol; 2006 Dec 01; 94(7):619-23. PubMed ID: 17111392
    [Abstract] [Full Text] [Related]

  • 17. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
    de Bruijn HW, Sleijfer DT, Schraffordt Koops H, Suurmeijer AJ, Marrink J, Ockhuizen T.
    Cancer; 1985 Feb 15; 55(4):829-35. PubMed ID: 2578303
    [Abstract] [Full Text] [Related]

  • 18. The predictive value of pre-orchidectomy serum tumor markers in non seminomatous germ cell tumors of the testis (N.S.G.C.T.T.).
    Boccon-Gibod L, Le Doze H, Steg A.
    Prog Clin Biol Res; 1985 Feb 15; 203():93-5. PubMed ID: 2421347
    [Abstract] [Full Text] [Related]

  • 19. [The role of tumor markers in the treatment of germ cell tumor].
    Niwakawa M, Tobisu K.
    Gan To Kagaku Ryoho; 2001 Aug 15; 28(8):1159-65. PubMed ID: 11525037
    [Abstract] [Full Text] [Related]

  • 20. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Mann K, Clemm C, Wilmanns W.
    Anticancer Res; 1997 Aug 15; 17(4B):3047-9. PubMed ID: 9329598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.